Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13568

UPID:
IRF5_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q13568; A4D1J8; A8DUA8; A8DUA9; E7EQ16; E7EW54; Q1A7B4; Q64GA9; Q64GB1; Q64GB2; Q6RCM8; Q9BQF0

BACKGROUND:
The protein Interferon regulatory factor 5 is a key transcription factor in the immune system, essential for the expression of type I interferons and inflammatory cytokines. It acts downstream of toll-like receptors, playing a crucial role in the body's defense against pathogens by mediating the induction of IFN-alpha and IFN-beta genes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Interferon regulatory factor 5 could open doors to potential therapeutic strategies. Its direct association with autoimmune diseases such as Inflammatory bowel disease, Systemic lupus erythematosus, and Rheumatoid arthritis highlights its significance in developing targeted treatments, potentially revolutionizing the management of these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.